Abstract: The present technology relates to processes, compounds, compositions, and methods useful for coupling reactions. Also, the present disclosure provides for novel intermediates, compositions of matter, and processes relating to the Chk1 inhibitor, SRA737.
Type:
Application
Filed:
April 6, 2021
Publication date:
May 18, 2023
Inventors:
Michael SCHWAEBE, Thorsten ROSNER, Dalian ZHAO, Ross MILLER, Rich DULINA, Michael HUMORA, Stephen E. GOTTSCHLING
Abstract: Herein disclosed are methods of treatment administering SRA737 as a monotherapy or in a combination therapy useful for treating patients with cancer.
Type:
Application
Filed:
February 26, 2019
Publication date:
December 24, 2020
Inventors:
Christian Andrew HASSIG, Bryan William STROUSE, Ryan James HANSEN, Kenna Lynn ANDERES, Snezana MILUTINOVIC, Angie J. YOU, Barbara KLENCKE, Mark KOWALSKI
Abstract: Disclosed herein are methods of treatment by administering SRA737 as a monotherapy or in a combination therapy that is useful for treating patients with cancer.
Type:
Application
Filed:
March 26, 2020
Publication date:
June 16, 2022
Applicants:
Sierra Oncology, Inc., The University of Texas M.D. Anderson Cancer Center
Inventors:
Christian Andrew Hassig, Snezana Milutinovic, Ryan James Hansen, Bryan William Strouse, Lauren Byers, Triparna Sen
Abstract: Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer. In particular, the combination demonstrates remarkable synergistic effects on cancer cells that are representative models for tumors. Also provided for are methods for treating disorders or diseases mediated or affected by Chk1 and/or PARP activity.
Type:
Application
Filed:
April 10, 2018
Publication date:
March 18, 2021
Inventors:
Christian Andrew HASSIG, Bryan William STROUSE, Ryan James HANSEN, Kenna Lynn ANDERES
Abstract: Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer. In particular, the combination demonstrates remarkable synergistic effects on cancer cells that are representative models for tumors. Also provided for are methods for treating disorders or diseases mediated or affected by Chk1 and/or PARP activity.
Type:
Grant
Filed:
April 10, 2018
Date of Patent:
March 7, 2023
Assignee:
Sierra Oncology, Inc.
Inventors:
Christian Andrew Hassig, Bryan William Strouse, Ryan James Hansen, Kenna Lynn Anderes
Abstract: This disclosure provides methods of using a checkpoint kinase 1 (Chk1) inhibitor in the treatment of cancer in a subject having at least an intermediate tumor mutational burden (TMB), or a genetic abnormality in one or more particular genes associated with replicative stress. Accordingly, methods of treating cancer in a subject having at least an intermediate tumor mutational burden (TMB-I) are provided. Also provided are methods of treating cancer in a subject having a genetic abnormality in one or more particular genes selected from cell cycle regulation genes, replication stress genes, oncogenic driver mutations and DNA damage response and repair network genes. Methods of selecting subjects for Chk1 inhibition therapy are provided. The methods can include administering to the subject an effective amount of a SRA737 compound, in some cases in combination with low dose gemcitabine.
Type:
Application
Filed:
May 13, 2020
Publication date:
July 21, 2022
Applicant:
Sierra Oncology, Inc.
Inventors:
Christian Andrew Hassig, Bryan William Strouse, Ryan James Hansen, Kenna Lynn Anderes, Snezana Milutinovic, Angie J. You, Barbara Jane Klencke, Mark Kowalski